Key points:
- Semaglutide patents have expired in countries including Brazil and India, allowing generic drug production.
- Legal disputes are emerging as Novo Nordisk seeks to extend patent protections and challenge generic manufacturers.
- Market dynamics are shifting, with increased competition and potential price reductions for semaglutide-based treatments.
The expiration of patents for semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, is reshaping the pharmaceutical landscape. In countries like Brazil and India, these expirations have opened the market to generic manufacturers, leading to legal disputes and significant market shifts.
In Brazil, the Superior Court of Justice recently denied Novo Nordisk's request to extend the semaglutide patent, maintaining its expiration in March 2026. This decision allows generic versions to enter the Brazilian market, potentially reducing costs and increasing accessibility for patients. ([chambers.com](https://chambers.com/articles/brazil-s-superior-court-of-justice-upholds-expiration-of-semaglutide-patent-ozempic?utm_source=openai))
Similarly, in India, the patent expiration has led to the introduction of generic semaglutide products by local pharmaceutical companies such as Sun Pharma, Dr. Reddy's, and Glenmark. These generics are priced significantly lower than the original, making the treatment more affordable for a broader population. ([cincodias.elpais.com](https://cincodias.elpais.com/companias/2026-03-23/la-india-comienza-a-vender-ozempic-hasta-un-80-mas-barato-tras-la-liberalizacion-de-la-patente-de-novo-nordisk.html?utm_source=openai))
However, Novo Nordisk is actively seeking to protect its market share. The company has urged the U.S. Food and Drug Administration (FDA) to prevent compounding pharmacies from producing semaglutide copies, citing concerns over the complexity and safety of replication. ([axios.com](https://www.axios.com/2024/10/24/novo-fda-compounders-ozempic-copies?utm_source=openai))
In the United States, semaglutide patents are set to expire in the early 2030s, with the earliest generic entry projected around December 2031. This timeline may be influenced by ongoing patent challenges and settlements. ([drugpatentwatch.com](https://www.drugpatentwatch.com/p/alphasignals/tradename/OZEMPIC?utm_source=openai))
The global pharmaceutical market is witnessing a shift as semaglutide patents expire. While this opens opportunities for generic manufacturers and could lead to more affordable treatments, it also prompts legal battles as original patent holders strive to maintain exclusivity. The outcome of these disputes will significantly impact the availability and pricing of semaglutide-based therapies worldwide.